Mineralys Therapeutics, Inc.
MLYS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $169 | $70 | $26 | $16 |
| G&A Expenses | $24 | $14 | $5 | $2 |
| SG&A Expenses | $24 | $14 | $5 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $192 | $85 | $31 | $19 |
| Operating Income | -$192 | -$85 | -$31 | -$19 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $15 | $13 | $2 | -$1 |
| Pre-Tax Income | -$178 | -$72 | -$30 | -$19 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$178 | -$72 | -$30 | -$19 |
| % Margin | – | – | – | – |
| EPS | -3.66 | -1.99 | -5.77 | -3.89 |
| % Growth | -83.9% | 65.5% | -48.3% | – |
| EPS Diluted | -3.66 | -1.99 | -5.77 | -3.89 |
| Weighted Avg Shares Out | 49 | 36 | 5 | 5 |
| Weighted Avg Shares Out Dil | 49 | 36 | 5 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15 | $13 | $2 | $0 |
| Interest Expense | $0 | $0 | $2 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$192 | -$85 | -$31 | -$19 |
| % Margin | – | – | – | – |